GlassScriptPhysician profile
Peter Lynn Jewell
NPI 1679779052
$2,530.50
in general payments reported to CMS, 2019-2025
30 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.25 · 2020: $55.43 · 2021: $243 · 2022: $616 · 2023: $744 · 2024: $449 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $402.89 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Axonics, INC. | $315.15 | 2022-2024 | Axonics |
| Abbvie INC. | $236.97 | 2022-2024 | |
| Lilly USA, LLC | $204.12 | 2022-2024 | Emgality, Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.53 | 2021-2023 | Jardiance |
| Amgen INC. | $163.28 | 2020-2024 | Otezla, Repatha |
| Medtronic, INC. | $141.42 | 2021-2024 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $122.26 | 2022-2023 | |
| Novo Nordisk INC | $121.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $100.41 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $88.53 | 2021-2024 | Airsupra, Farxiga |
| Pfizer INC. | $70.56 | 2019-2022 | |
| Insulet Corporation | $70.44 | 2020-2024 | Omnipod |
| Abbott Laboratories | $42.22 | 2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $26.65 | 2022-2023 | Arexvy, Bexsero, Shingrix |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $25.24 | 2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $24.27 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.41 | 2023 | Trulance, Xifaxan |
| Xeris Pharmaceuticals, INC. | $17.98 | 2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $17.98 | 2021 | |
| Smith+Nephew, INC. | $17.64 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.52 | 2023 | Xarelto |
| Depuy Synthes Sales INC. | $16.11 | 2024 | Orthovisc, Monovisc |
| Genentech, INC. | $14.86 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.46 | 2023 | Quviviq |
| Allergan, INC. | $13.04 | 2020 | |
| Genzyme Corporation | $12.71 | 2021 | |
| Boston Scientific Corporation | $11.63 | 2019 | |
| Corcept Therapeutics | $11.22 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Jewell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.